NEW YORK (GenomeWeb) – Seattle-based cancer immunotherapy company Juno Therapeutics has acquired AbVitro of Boston for approximately $78 million in cash and almost 1.3 million shares of its stock, the company said today.

In addition, Juno and Celgene have agreed in principle on a deal under which Celgene will license a subset of AbVitro's technology and have options to certain potential products deriving from it.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.